Navigation Links
Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema

BASEL, Switzerland, April 25, 2007 - Basilea Pharmaceutica Ltd. (SWX:BSLN) reported today phase III study results showing that patients with severe chronic hand eczema can benefit from re-treatment with alitretinoin. In two previous randomized clinical trials, alitretinoin was found to be effective in treating severe chronic hand eczema in patients refractory to topical treatments. This pivotal trial demonstrated that patients responsive to initial treatment with alitretinoin can also benefit from additional treatment courses after eventual disease recurrence. The safety profile of alitretinoin observed in this study was consistent with that seen in previous trials. These positive data will be integrated into regulatory submissions planned for later this year.

Severe refractory Chronic Hand Eczema (CHE) is a relapsing disorder for which no approved treatment currently exists. This debilitating disease prevents patients from using their hands normally and requires frequent treatment interventions over time.

The objective of this re-treatment study was to describe the safety and efficacy of a second treatment course of alitretinoin in patients who achieved clear or almost clear hands after a previous initial treatment course. This study included 117 patients who eventually had disease recurrence, and 243 patients who had incomplete response after the initial treatment trial.

Patients who had disease recurrence were randomized in double blind manner to receive another 12 to 24 weeks treatment with either placebo or their previous dose of alitretinoin. Response rates were 80% for the alitretinoin 30mg group (Placebo 8.3%) and 48% for the 10mg group (Placebo 10%). These results indicate that alitretinoin is effective in treating severe refractory CHE in subsequent treatment courses.

Those patients who had either no or an incomplete response in the previous study received 30mg alitretinoin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
2. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, ... Boston and their first West Coast location in ... Street in Boston , and will house product ... Southern California office will be located at ... the demands of customers nationwide.  Both new locations will be ...
(Date:9/16/2014)... Sept. 16, 2014  Formex, LLC ("Formex"), ... that Mr. Greg Weilersbacher joined Formex as Director ... Greg Weilersbacher has ... focused expertise in Quality Assurance, Facility Validation, ... Weilersbacher brings to Formex a diverse wealth ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... R.I., Aug. 16, 2011 Medicare Part D beneficiaries ... pay 100 percent of previously subsidized prescription costs, are ... are to switch to more affordable or generic medications, ... concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) The ...
... Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... Phase III clinical studies in patients with refractory chronic ... of the American Medical Association ( JAMA ). ... significant and sustained reductions in uric acid levels along ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:9/16/2014)... pain clinic as a testing ground, researchers at Johns ... by Toyota in Japan can substantially reduce patient wait ... residents. , In a report on the pilot study, ... the researchers adopted the so-called "Just-in-Time" training and inventory ... to stem waste and keep complicated operations from bottlenecking. ...
(Date:9/16/2014)... Va. (PRWEB) September 16, 2014 ... through predictive analytics and targeted clinical programs, today ... announced changes support the Company’s drive to improve ... and targeted clinical programs. On September 2, 2014, ... company, Millennium Health, announced that RxAnte founder and ...
(Date:9/16/2014)... Thompson HealthDay Reporter MONDAY, ... strong heart fitness can delay a man,s onset of age-related ... suggests. Blood pressure naturally increases as people grow older ... with strong cardio-fitness don,t start drifting toward high blood pressure ... usually experience the early signs of high blood pressure in ...
(Date:9/16/2014)... early-stage lung cancer who receive stereotactic body radiation ... 40 percent, according to research presented today at ... Annual Meeting. Such a positive survival rate is ... poor tumor control for patients with inoperable lung ... 0236, originally published in 2010 , and also ...
(Date:9/16/2014)... West Orange, NJ. September 16, 2014. Kessler Foundation ... of slowed processing speed in the executive deficits ... "Does slowed processing speed account for executive deficits ... structural neuroimaging," was published online ahead of print ... The authors are Victoria Leavitt, PhD, ...
Breaking Medicine News(10 mins):Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3
... ... in designing cutting-edge training facility for Kodak Dental Systems that features practice management ... ... August 4, 2009 -- Advanced Automation, a leader in comprehensive IT solutions and ...
... , ROSEMONT, Ill., Aug. 4 ... such anesthetic drugs as Diprivan (propofol) by the late Michael Jackson, ... agents. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO ... and Maxillofacial Surgeons (AAOMS) and its 8,500 fellows and members who ...
... , , , ... (Pink Sheets: NXCO), developer of next generation digital media protection ... , a website that provides authors in the self-help/motivational market ... their downloadable materials. AmnestyQuest.com is a partnership between Nexicon and ...
... MINNEAPOLIS, Aug. 4 Court ordered Class Notice in Curtis, et al., ... , court File No. 27-CV-01-18042 (action filed 11/28/01). , , ... at any time before November 30, 2004, this class action notice may affect ... the marketing, advertising and promotion of Marlboro Lights cigarettes is pending in Hennepin ...
... , AVENTURA, Fla., Aug. 4 ... of highly specialized, nationally recognized orthopedic surgeons who have agreed ... business model of Centers of Excellence with Global Convenience(TM) ... orthopedic procedures domestically and abroad. The team represents a total ...
... ... has introduced a new technology offering including their new Scoreboard application. ... at a glance screen showing key business indicators updated in real-time. ... or both. The Scoreboard will be available to clients that either ...
Cached Medicine News:Health News:New Kodak Training Facility Showcases the Latest in Dental Technology, Solutions from Advanced Automation: Networking Solutions, Dental Practice Management and Dental X-Ray Integration 2Health News:New Kodak Training Facility Showcases the Latest in Dental Technology, Solutions from Advanced Automation: Networking Solutions, Dental Practice Management and Dental X-Ray Integration 3Health News:American Association of Oral and Maxillofacial Surgeons Says Only Trained Dental and Medical Practitioners Should Administer and Monitor Anesthesia 2Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 2Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 3Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 4Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 5Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 3Health News:Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons 2Health News:Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons 3Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: